How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

18,224 results for

"grant funding" or "obtaining grants" or "getting grants" or "grant awards" or (grants and "how to")

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

17701. Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

: LCCC 0418 KG100307 ( Other Grant/Funding Number: Susan G Komen for the Cure ) First Posted: December 15, 2005 Results First Posted: May 9, 2017 Last Update Posted: September 12, 2018 Last Verified: August 2018 Keywords provided by UNC Lineberger Comprehensive Cancer Center: stage IV breast cancer recurrent breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Vaccines Sargramostim Trastuzumab Vinorelbine (...) : This phase II trial is studying how well giving vaccine therapy together with trastuzumab and vinorelbine works in treating patients with locally recurrent or metastatic breast cancer. Condition or disease Intervention/treatment Phase Breast Cancer Biological: sargramostim Biological: therapeutic autologous dendritic cells Biological: trastuzumab Drug: vinorelbine ditartrate Phase 2 Detailed Description: OBJECTIVES: Primary Determine the efficacy of multiepitope autologous dendritic cell vaccine

2005 Clinical Trials

17702. An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study

17, 2017 Sponsor: Hospital for Special Surgery, New York Collaborators: Genzyme, a Sanofi Company National Institutes of Health (NIH) Information provided by (Responsible Party): Hospital for Special Surgery, New York Study Details Study Description Go to Brief Summary: The purpose of this study is to find out if hyaluronan, an injectable medication for knee arthritis, also works for arthritis at the base of the thumb. This study will also evaluate how good ultrasound is at visualizing medication (...) to a 0-100 scale, with a higher value indicating greater disability. The change in DASH (delta) over those 6 months was recorded. Secondary Outcome Measures : Visual Analog Scale for Pain [ Time Frame: 26 weeks (6 months) ] The visual analog scale for pain (VAS) is a test requiring a patient to indicate along a line how much pain they are experiencing between 0-100. A score of 100 indicates the maximum possible pain level and a score of 0 indicates no pain. Scores are recorded as whole number

2005 Clinical Trials

17703. Nutrition, Immunology and Epidemiology of Tuberculosis

the inter- relationships of nutrition, immunology, and epidemiology with respect to TB in Tanzania. Given that TB is so much linked with HIV immunologically, clinically, and epidemiologically, it is essential to examine how these relationships are modified by HIV infection. Published animal and human studies suggest that vitamin deficiency is associated with poor immune response in TB. By modulating immune function, nutritional supplements may be a useful adjunct to anti-TB drugs, and could lead (...) research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Men and women, age 18 to 60 years inclusive At least two positive sputum smears for tuberculosis Intention to stay in Dar-es-Salaam for at least 2 years after the start of TB therapy Subjects who grant informed consent to participation

2005 Clinical Trials

17704. The Impact of Vocational Rehabilitation for Mentally Ill Veterans

of Veterans Affairs ClinicalTrials.gov Identifier: Obsolete Identifiers: NCT00260507 Other Study ID Numbers: D4092-I Promis Number 0052 ( Other Grant/Funding Number: TVAMC ) MIRB 00033 ( Other Identifier: TVAMC - reference number ) TVAMC 03-19 ( Other Identifier: TVAMC - Year/project number ) First Posted: June 6, 2006 Results First Posted: March 19, 2015 Last Update Posted: March 19, 2015 Last Verified: March 2015 Keywords provided by VA Office of Research and Development ( US Department of Veterans

2005 Clinical Trials

17705. Transition Into Primary-care Psychiatry (TIPP)

. Joseph's Care Group Investigators Layout table for investigator information Principal Investigator: David RS Haslam, MSc MD FRCPC St. Joseph's Health Care London Principal Investigator: John M Haggarty, BSc MD FRCPC St. Joseph's Care Group More Information Go to Layout table for additonal information Responsible Party: Dr. David S. Haslam, Lawson Health Research Institute ClinicalTrials.gov Identifier: Other Study ID Numbers: R-04-093 G03-05687 ( Other Grant/Funding Number: Government of Ontario G03 (...) Information provided by: Lawson Health Research Institute Study Details Study Description Go to Brief Summary: The objective of the Transition into Primary-care Psychiatry (TIPP) project is to determine how feasible it is to conduct a study to evaluate a new primary-care focused program of mental health care delivery for people with chronic mental illness. This will be done by comparing a primary-care based collaborative, interdisciplinary model to care-as-usual on health related quality of life, client

2005 Clinical Trials

17706. Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs

information Study Chair: Ji-Wang Chern, Ph.D. National Taiwan University Principal Investigator: Wen-Je Ko, M.D, Ph.D National Taiwan University Hospital Principal Investigator: Fe-Lin Lin, Ph.D. National of University Study Director: Chiung-Hua Huang, M.S National Taiwan University More Information Go to Layout table for additonal information Responsible Party: National Taiwan University Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: 9361701301 DOH94-td-d-113-035(2) ( Other Grant/Funding (...) , antineoplastic, or antivirus drugs that are used extensively in clinical settings bear the risk of nephrotoxicity. This side effect is dose-dependent and has been attributed mainly to the accumulation of drugs in the renal proximal tubule. When assessing nephrotoxicity, both the dosage and the tubular secretion system, which allows transport of drug from blood to urine via the tubular cells, are important factors. This study was designed to investigate how renal transporters work in the renal secretion

2005 Clinical Trials

17707. Electrothermal Arthroscopic Capsulorrhaphy (ETAC) and Open Inferior Capsular Shift in Patients With Shoulder Instability

ClinicalTrials.gov Identifier: Other Study ID Numbers: 10650 MCT-64671 (CIHR) ( Other Grant/Funding Number: Canadian Institutes of Health Research ) ISRCTN68224911 ( Registry Identifier: Current Controlled Trials ) First Posted: November 9, 2005 Last Update Posted: July 13, 2015 Last Verified: July 2015 Keywords provided by Dr. Nicholas Mohtadi, University of Calgary: Multi-directional instability MDI Ligamentous laxity Multi-directional laxity MDL-AII Shoulder instability electrothermal capsulorrhaphy, ETAC

2005 Clinical Trials

17708. Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals

individuals. Condition or disease Cocaine Abuse Cocaine-Related Disorders Detailed Description: Cocaine is a strong central nervous system stimulant that is widely abused throughout the United States. Due to its widespread use, it is important to develop an effective treatment for cocaine dependence. The purpose of this study is to determine how impulsivity and prefrontal cortical function are related to treatment response in cocaine dependent individuals. Participants in this study will complete four (...) ) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Sampling Method: Probability Sample Study Population Cocaine Dependent Subjects Criteria Inclusion Criteria: Meets DSM-IV criteria for cocaine dependence Met inclusion criteria for other cocaine dependence studies within the center grant Exclusion Criteria: Current or history of DSM-IV Axis I disorders, other than substance abuse or dependence Lifetime diagnosis of alcohol dependence Serious non-psychiatric medical illness requiring

2005 Clinical Trials

17709. Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with antiviral therapy followed by effusion drainage, bevacizumab, and combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with antiviral therapy followed by effusion drainage, bevacizumab (...) ClinicalTrials.gov identifier (NCT number): NCT00217503 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 Sponsors and Collaborators National Cancer Institute (NCI) Investigators Layout table for investigator information Principal Investigator: Richard F. Little, MD NCI - HIV and AIDS Malignancy Branch More Information Go to Layout table for additonal information

2005 Clinical Trials

17710. Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia

Philadelphia, Pennsylvania, United States, 19107 Sponsors and Collaborators Thomas Jefferson University Investigators Layout table for investigator information Principal Investigator: Marlind A Stiles, D.M.D. Thomas Jefferson University, Jefferson Headache Center More Information Go to Layout table for additonal information Responsible Party: Thomas Jefferson University ClinicalTrials.gov Identifier: Other Study ID Numbers: MAS/LAM101 H92001 ( Other Grant/Funding Number: GlaxoSmithKline ) First Posted (...) First Posted : June 3, 2014 Last Update Posted : June 3, 2014 Sponsor: Thomas Jefferson University Information provided by (Responsible Party): Thomas Jefferson University Study Details Study Description Go to Brief Summary: This research study will look at the safety (e.g., the occurrence of side effects) and efficacy (how well the drug works in reducing trigeminal neuralgia attacks) of a drug called lamotrigine in adults with trigeminal neuralgia. Condition or disease Intervention/treatment Phase

2005 Clinical Trials

17711. Childhood Origins of Asthma (COAST)

interaction that needs to occur at a critical time period in the development of the immune system or the lung. It remains to be firmly established, however, how any one or all of these factors, either independently or interactively, influence the development of childhood asthma. Thus, our efforts to determine and define the importance of these three factors to asthma pathogenesis are the focus and goal of this current grant application. Condition or disease Asthma Allergy Detailed Description: No more

2005 Clinical Trials

17712. Soy Protein and Breast Cancer Risk Reduction

Identifier (NCT Number): Layout table for additonal information Responsible Party: The University of Texas Medical Branch, Galveston ClinicalTrials.gov Identifier: Other Study ID Numbers: 02-422 Army's HSRRB log no. A-10926 ( Other Identifier: USA MRMC Human Research Protection Office (HRPO) ) UTMB GCRC 533 ( Other Identifier: UTMB ITSCRC ) DAMD17-01-1-0417 ( Other Grant/Funding Number: USA MRMC ) First Posted: September 20, 2005 Last Update Posted: March 15, 2019 Last Verified: March 2019 Individual

2005 Clinical Trials

17713. Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer

Identifier: Other Study ID Numbers: CDR0000443617 OHSU-CI-CPC-04131-LX ( Other Identifier: OHSU Knight Cancer Institute number ) VAMC-04-0303/ M1016 ( Other Identifier: Portland VA IRB number ) DOD-W81XWH-04-1-0296 ( Other Grant/Funding Number: Dept of Defense Award Number ) OHSU-1117 ( Other Identifier: OHSU IRB number ) KPNW-NW-05SLIEB-01 ( Other Identifier: Kaiser Permanente NW IRB number ) First Posted: November 15, 2005 Results First Posted: February 18, 2015 Last Update Posted: April 18, 2017 Last (...) and/or green tea may prevent prostate cancer. PURPOSE: This randomized clinical trial is studying how well a fish oil and/or green tea supplement works in preventing prostate cancer in patients with prostatic intraepithelial neoplasia or who are at risk for developing prostate cancer. Condition or disease Intervention/treatment Phase Precancerous Condition Prostate Cancer Dietary Supplement: green tea catechin extract Dietary Supplement: fish oil Other: placebo Not Applicable Detailed Description

2005 Clinical Trials

17714. Patient Centered Randomized Controlled Trial

of adjuvant therapies among minority and nonminority women with newly operated early-stage breast cancer. During the 24 month trial, we will assess patients' beliefs about cancer and its treatment, and their practical, psychosocial, and informational needs and barriers to care. We will identify and train employees in existing cancer assistance services in order to increase the sustainability of this program beyond the grant-funded cycle. Specifically, we propose: To assess racial differences in early (...) table for investigator information Principal Investigator: Nina A Bickell, MD Icahn School of Medicine at Mount Sinai More Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: Icahn School of Medicine at Mount Sinai ClinicalTrials.gov Identifier: Other Study ID Numbers: GCO 03-0593 1R01CA10705-01A1 ( Other Grant/Funding Number: NCI ) First Posted: October 5, 2005 Last Update Posted

2005 Clinical Trials

17715. Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

Psychiatrist, Nathan Kline Institute for Psychiatric Research ClinicalTrials.gov Identifier: Other Study ID Numbers: 04T-584 Stanley Foundation 04T-584 ( Other Grant/Funding Number: Stanley Foundation ) First Posted: October 4, 2005 Results First Posted: December 11, 2017 Last Update Posted: December 11, 2017 Last Verified: November 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies

2005 Clinical Trials

17716. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial

the onset of advanced kidney disease and heart and blood vessel problems such as heart attack, stroke and death, to a greater extent than usual care. The study will also address issues of costs associated with care and illness. The nature of the care provided by the heatlh care professionals will be studied to see how best to achieve good health outcomes. Condition or disease Intervention/treatment Phase Chronic Kidney Disease Procedure: Combined CKD and CVD Prevention Procedure: Cardiovascular Disease (...) with regard to short-term quality-of-life outcomes. Phase1 How long does it take to recruit 100 patients per study site? What recruitment strategies are most efficient? How do the baseline characteristics of those recruited compare to referred populations, and to the general population with CKD? How do the nephrologist and nurse work together to provide care to those in the intervention group? What is the nature of the care provided by the nurses and physicians to those in the intervention group

2005 Clinical Trials

17717. Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Comprehensive Cancer Center More Information Go to Additional Information: Publications of Results: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: UNC Lineberger Comprehensive Cancer Center ClinicalTrials.gov Identifier: Obsolete Identifiers: NCT00420329, NCT00492375 Other Study ID Numbers: LCCC 0403 CA058223 ( Other Grant/Funding Number: NCI OSP/SPOREs ) First Posted: October 4, 2005 Results First (...) with carboplatin is more effective than giving cetuximab alone in treating metastatic breast cancer. PURPOSE: This randomized phase II trial is studying cetuximab and carboplatin to see how well they work compared with cetuximab alone in treating women with estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) metastatic breast cancer. Condition or disease Intervention/treatment Phase Breast Cancer Biological: cetuximab Drug: carboplatin Phase 2 Detailed Description: OBJECTIVES: Primary

2005 Clinical Trials

17718. Vertebral Osteosynthesis in Degenerative Lumbar Stenosis With Spondylolisthesis

department Toulouse, France, 31059 Sponsors and Collaborators University Hospital, Toulouse Investigators Layout table for investigator information Principal Investigator: Jacques Lagarrigue Toulouse University Hospital More Information Go to Publications: Layout table for additonal information Responsible Party: University Hospital, Toulouse ClinicalTrials.gov Identifier: Other Study ID Numbers: 0300201 PHRC0300201 ( Other Grant/Funding Number: French Ministry of Health ) First Posted: November 11, 2005

2005 Clinical Trials

17719. ADAPT-POL New Orleans: Adaptation of Prevention Techniques With Popular Opinion Leader

for additonal information Responsible Party: Centers for Disease Control and Prevention ClinicalTrials.gov Identifier: Other Study ID Numbers: CDC-NCHSTP-U65/CCU623818 U65/CCU623818-01-1 ( Other Grant/Funding Number: CDC ) First Posted: November 11, 2005 Last Update Posted: August 16, 2012 Last Verified: August 2012 Keywords provided by Centers for Disease Control and Prevention: HIV Seropositive MSM African American Popular Opinion Leader Additional relevant MeSH terms: Layout table for MeSH terms HIV (...) is a community-level, evidence-based HIV prevention intervention that originally targeted gay and bisexual men in smaller cities throughout the United States. Kelly's intervention seeks to identify and enlist the support of well-known and well-liked opinion leaders to take on risk reduction advocacy roles. Opinion leaders attend sessions to learn how to engage in risk reduction conversations with people in their own social networks. The opinion leaders help to reshape social norms to encourage safer sex

2005 Clinical Trials

17720. Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption

Study ID Numbers: 433-2005 7591 ( Other Grant/Funding Number: UF Clinical Research Center ) First Posted: October 10, 2005 Results First Posted: December 14, 2011 Last Update Posted: December 22, 2011 Last Verified: December 2011 Keywords provided by University of Florida: Vitamin B12 absorption Holo-transcobalamin Additional relevant MeSH terms: Layout table for MeSH terms Vitamins Hydroxocobalamin Vitamin B 12 Vitamin B Complex Micronutrients Nutrients Growth Substances Physiological Effects

2005 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>